PDF herunterladen
Semin Neurol 2020; 40(03): 342-348
DOI: 10.1055/s-0040-1705120
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Juvenile Dermatomyositis and the Inflammatory Myopathies

Collin Swafford
1   Department of Neurology, Dell Medical School, University of Texas, Austin, Texas
,
E. Steve Roach
1   Department of Neurology, Dell Medical School, University of Texas, Austin, Texas
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. April 2020 (online)

  Lizenzen und Reprints

Abstract

The inflammatory myopathies comprise disorders of immune-mediated muscle injury. The histopathology and clinical features help distinguish them. Juvenile dermatomyositis (JDM) is the most common form of myositis in children and adolescents. Children with JDM present with proximal muscle weakness and characteristic rashes. The presentation is similar in children and adults, but JDM is a primary disorder and the adult form often is concerning for a paraneoplastic syndrome. Proximal muscle weakness occurs with dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy, but the latter two conditions have no dermatologic findings or distinct tissue changes which set them apart from dermatomyositis. Inclusion body myositis, also included in the inflammatory myopathies, presents with more distal involvement, and microscopically exhibits identifiable rimmed vacuoles. We review key features of these disorders, focusing in more detail on JDM because it is more often encountered by the child neurologist.

Keywords

Inflammatory myopathies - juvenile dermatomyositis - inclusion body myositis - immune-mediated necrotizing myopathy
 

  • References

  • 1 Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016; 280 (01) 24-38
    CrossrefPubMedSuche in Google Scholar
  • 2 Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371 (9631): 2201-2212
    CrossrefPubMedSuche in Google Scholar
  • 3 Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol 1991; 32 (04) 235-240
    CrossrefPubMedSuche in Google Scholar
  • 4 Mamyrova G, Rider LG, Ehrlich A. , et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology (Oxford) 2017; 56 (08) 1342-1347
    CrossrefPubMedSuche in Google Scholar
  • 5 Massa M, Costouros N, Mazzoli F. , et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 2002; 46 (11) 3015-3025
    CrossrefPubMedSuche in Google Scholar
  • 6 Bowles NE, Dubowitz V, Sewry CA, Archard LC. Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1987; 1 (8540): 1004-1007
    PubMedSuche in Google Scholar
  • 7 Kwa MC, Silverberg JI, Ardalan K. Inpatient burden of juvenile dermatomyositis among children in the United States. Pediatr Rheumatol Online J 2018; 16 (01) 70
    CrossrefPubMedSuche in Google Scholar
  • 8 Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A. Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools. Front Immunol 2018; 9: 2951
    CrossrefPubMedSuche in Google Scholar
  • 9 Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr 2018; 6: 284
    CrossrefPubMedSuche in Google Scholar
  • 10 Lundberg I, Ulfgren A-K, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40 (05) 865-874
    CrossrefPubMedSuche in Google Scholar
  • 11 Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis 2018; 5 (02) 109-129
    CrossrefPubMedSuche in Google Scholar
  • 12 Harris-Love MO, Shrader JA, Koziol D. , et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009; 48 (02) 134-139
    CrossrefPubMedSuche in Google Scholar
  • 13 Na S-J, Kim SM, Sunwoo IN, Choi Y-C. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J Korean Med Sci 2009; 24 (04) 715-721
    CrossrefPubMedSuche in Google Scholar
  • 14 Malleson P. Juvenile dermatomyositis: a review. J R Soc Med 1982; 75 (01) 33-37
    PubMedSuche in Google Scholar
  • 15 Bellutti Enders F, Bader-Meunier B, Baildam E. , et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76 (02) 329-340
    CrossrefPubMedSuche in Google Scholar
  • 16 Al-Mayouf SM, AlMutiari N, Muzaffer M. , et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int 2017; 37 (09) 1513-1517
    CrossrefPubMedSuche in Google Scholar
  • 17 Kim S, Kahn P, Robinson AB. , et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J 2017; 15 (01) 1
    CrossrefPubMedSuche in Google Scholar
  • 18 Sevigny GM, Mathes BM. Periorbital edema as the presenting sign of juvenile dermatomyositis. Pediatr Dermatol 1999; 16 (01) 43-45
    CrossrefPubMedSuche in Google Scholar
  • 19 Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23 (03) 619-655
    CrossrefPubMedSuche in Google Scholar
  • 20 Dicken CH. Periorbital edema: an important physical finding in dermatomyositis. Cutis 1991; 48 (02) 116-117
    PubMedSuche in Google Scholar
  • 21 Woo TR, Rasmussen J, Callen JP. Recurrent photosensitive dermatitis preceding juvenile dermatomyositis. Pediatr Dermatol 1985; 2 (03) 207-212
    CrossrefPubMedSuche in Google Scholar
  • 22 Callen JP. Dermatomyositis. Lancet 2000; 355 (9197): 53-57
    CrossrefPubMedSuche in Google Scholar
  • 23 Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58 (02) 571-576
    CrossrefPubMedSuche in Google Scholar
  • 24 Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31 (08) 1644-1649
    PubMedSuche in Google Scholar
  • 25 Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 2014; 16 (12) 467
    CrossrefPubMedSuche in Google Scholar
  • 26 Lowry CA, Pilkington CA. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol 2009; 21 (06) 575-580
    CrossrefPubMedSuche in Google Scholar
  • 27 Kobayashi I, Yamada M, Takahashi Y. , et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42 (02) 371-374
    PubMedSuche in Google Scholar
  • 28 Kobayashi N, Takezaki S, Kobayashi I. , et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 2015; 54 (05) 784-791
    CrossrefPubMedSuche in Google Scholar
  • 29 Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J 2012; 6: 54-63
    CrossrefPubMedSuche in Google Scholar
  • 30 Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58 (11) 3585-3592
    CrossrefPubMedSuche in Google Scholar
  • 31 Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325 (21) 1487-1498
    PubMedSuche in Google Scholar
  • 32 Rider LG, Shah M, Mamyrova G. , et al; Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92 (04) 223-243
    PubMedSuche in Google Scholar
  • 33 Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity 2005; 38 (01) 73-78
    CrossrefPubMedSuche in Google Scholar
  • 34 Ukichi T, Yoshida K, Matsushima S. , et al. MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis. RMD Open 2019; 5 (01) e000850
    CrossrefPubMedSuche in Google Scholar
  • 35 Ladd PE, Emery KH, Salisbury SR, Laor T, Lovell DJ, Bove KE. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 2011; 197 (01) W153-W158
    CrossrefPubMedSuche in Google Scholar
  • 36 Pinto B, Janardana R, Nadig R. , et al. Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clin Rheumatol 2019; 38 (07) 1931-1934
    CrossrefPubMedSuche in Google Scholar
  • 37 Naim MY, Reed AM. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy. J Rheumatol 2006; 33 (07) 1392-1394
    PubMedSuche in Google Scholar
  • 38 Vattemi G, Mirabella M, Guglielmi V. , et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights 2014; 5 (03) 77-85
    PubMedSuche in Google Scholar
  • 39 Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 2006; 18 (05) 503-506
    CrossrefPubMedSuche in Google Scholar
  • 40 Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr 1984; 105 (03) 399-408
    CrossrefPubMedSuche in Google Scholar
  • 41 Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47 (04) 505-511
    CrossrefPubMedSuche in Google Scholar
  • 42 Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103 (06) 882-888
    CrossrefPubMedSuche in Google Scholar
  • 43 Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis 2012; 4 (01) 41-50
    CrossrefPubMedSuche in Google Scholar
  • 44 Heckmatt J, Hasson N, Saunders C. , et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1 (8646): 1063-1066
    PubMedSuche in Google Scholar
  • 45 Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996; 23 (08) 1424-1427
    PubMedSuche in Google Scholar
  • 46 Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011; 70 (12) 2089-2094
    CrossrefPubMedSuche in Google Scholar
  • 47 Oddis CV, Reed AM, Aggarwal R. , et al; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65 (02) 314-324
    CrossrefPubMedSuche in Google Scholar
  • 48 Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47 (06) 877-880
    CrossrefPubMedSuche in Google Scholar
  • 49 Dagher R, Desjonquères M, Duquesne A. , et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2012; 32 (03) 711-716
    CrossrefPubMedSuche in Google Scholar
  • 50 Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27 (11) 1469-1471
    CrossrefPubMedSuche in Google Scholar
  • 51 Batthish M, Feldman BM. Juvenile dermatomyositis. Curr Rheumatol Rep 2011; 13 (03) 216-224
    CrossrefPubMedSuche in Google Scholar
  • 52 Marvi U, Chung L, Fiorentino DF. Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol 2012; 57 (05) 375-381
    CrossrefPubMedSuche in Google Scholar
  • 53 Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther 2013; 15 (02) 211
    CrossrefPubMedSuche in Google Scholar
  • 54 Rider LG, Lachenbruch PA, Monroe JB. , et al; IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60 (11) 3425-3435
    CrossrefPubMedSuche in Google Scholar
  • 55 Hill CL, Zhang Y, Sigurgeirsson B. , et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357 (9250): 96-100
    CrossrefPubMedSuche in Google Scholar
  • 56 Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 2010; 32 (03) 189-191
    CrossrefPubMedSuche in Google Scholar
  • 57 Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002; 28 (04) 723-741
    CrossrefPubMedSuche in Google Scholar
  • 58 Hunter K, Lyon MG. Evaluation and management of polymyositis. Indian J Dermatol 2012; 57 (05) 371-374
    CrossrefPubMedSuche in Google Scholar
  • 59 Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 2018; 28 (06) 913-921
    CrossrefPubMedSuche in Google Scholar
  • 60 Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 2018; 20 (04) 21
    CrossrefPubMedSuche in Google Scholar
  • 61 Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 2015; 373 (17) 1680-1682
    CrossrefPubMedSuche in Google Scholar
  • 62 Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62 (09) 1328-1334
    PubMedSuche in Google Scholar
  • 63 Suzuki S, Ohta M, Shimizu Y, Hayashi YK, Nishino I. Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol 2011; 45 (02) 114-116
    CrossrefPubMedSuche in Google Scholar
  • 64 Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin 2014; 32 (03) 629-646 , vii
    CrossrefPubMedSuche in Google Scholar
  • 65 Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56 (03) 323-327
    CrossrefPubMedSuche in Google Scholar
  • 66 Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48 (03) 712-716
    CrossrefPubMedSuche in Google Scholar
  • 67 Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol 2009; 256 (12) 2009-2013
    CrossrefPubMedSuche in Google Scholar
  • 68 Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil 2008; 87 (11) 883-889
    CrossrefPubMedSuche in Google Scholar